1
|
Lee G, Sou SM, Twerenbold R, Reichlin T,
Oshima S, Hochgruber T, Zürcher S, Matter D, Tanglay Y, Freese M,
et al: B-type natriuretic peptide and clinical judgment in the
detection of exercise-induced myocardial ischemia. Am J Med.
127:427–435. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bell RM and Yellon DM: Conditioning the
whole heart - not just the cardiomyocyte. J Mol Cell Cardiol.
53:24–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hausenloy DJ, Tsang A, Mocanu MM and
Yellon DM: Ischemic preconditioning protects by activating
prosurvival kinases at reperfusion. Am J Physiol Heart Circ
Physiol. 288:H971–H976. 2005. View Article : Google Scholar
|
4
|
Zeymer U, Bauer T, Gersh BJ, Zahn R, Gitt
A, Jünger C and Senges J: Beneficial effect of reperfusion therapy
beyond the preservation of left ventricular function in patients
with acute ST-segment elevation myocardial infarction. Int J
Cardiol. 146:177–180. 2011. View Article : Google Scholar
|
5
|
Braunwald E and Kloner RA: Myocardial
reperfusion: A double-edged sword? J Clin Invest. 76:1713–1719.
1985. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lin J-Y, Hung L-M, Lai LY and Wei F-C:
Kappa-opioid receptor agonist protects the microcirculation of
skeletal muscle from ischemia reperfusion injury. Ann Plast Surg.
61:330–336. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Nallamothu BK, Bradley EH and Krumholz HM:
Time to treatment in primary percutaneous coronary intervention. N
Engl J Med. 357:1631–1638. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Niccoli G, Burzotta F, Galiuto L and Crea
F: Myocardial no-reflow in humans. J Am Coll Cardiol. 54:281–292.
2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Jordan JE, Zhao ZQ and Vinten-Johansen J:
The role of neutrophils in myocardial ischemia-reperfusion injury.
Cardiovasc Res. 43:860–878. 1999. View Article : Google Scholar
|
10
|
Ito H, Maruyama A, Iwakura K, Takiuchi S,
Masuyama T, Hori M, Higashino Y, Fujii K and Minamino T: Clinical
implications of the 'no reflow' phenomenon. A predictor of
complications and left ventricular remodeling in reperfused
anterior wall myocardial infarction. Circulation. 93:223–228. 1996.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Ndrepepa G, Tiroch K, Fusaro M, Keta D,
Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schömig A, et
al: 5-year prognostic value of no-reflow phenomenon after
percutaneous coronary intervention in patients with acute
myocardial infarction. J Am Coll Cardiol. 55:2383–2389. 2010.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Xu X, Li Z and Gao W: Growth
differentiation factor 15 in cardiovascular diseases: From bench to
bedside. Biomarkers. 16:466–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Hsiao EC, Koniaris LG, Zimmers-Koniaris T,
Sebald SM, Huynh TV and Lee SJ: Characterization of
growth-differentiation factor 15, a transforming growth factor β
superfamily member induced following liver injury. Mol Cell Biol.
20:3742–3751. 2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kempf T, Eden M, Strelau J, Naguib M,
Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin
JD, et al: The transforming growth factor-β superfamily member
growth-differentiation factor-15 protects the heart from
ischemia/reperfusion injury. Circ Res. 98:351–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Bonaca MP, Morrow DA, Braunwald E, Cannon
CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L and
Wollert KC: Growth differentiation factor-15 and risk of recurrent
events in patients stabilized after acute coronary syndrome:
Observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol.
31:203–210. 2011. View Article : Google Scholar
|
16
|
Anand IS, Kempf T, Rector TS, Tapken H,
Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H and Wollert
KC: Serial measurement of growth-differentiation factor-15 in heart
failure: Relation to disease severity and prognosis in the
Valsartan Heart Failure Trial. Circulation. 122:1387–1395. 2010.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Kempf T, Zarbock A, Widera C, Butz S,
Stadtmann A, Rossaint J, Bolomin-Vittori M, Korf-Klingebiel M, Napp
LC, Hansen B, et al: GDF-15 is an inhibitor of leukocyte integrin
activation required for survival after myocardial infarction in
mice. Nat Med. 17:581–588. 2011. View
Article : Google Scholar : PubMed/NCBI
|
18
|
Eitel I, Blase P, Adams V, Hildebrand L,
Desch Sm, Schuler G and Thiele H: Growth-differentiation factor 15
as predictor of mortality in acute reperfused ST-elevation
myocardial infarction: insights from cardiovascular magnetic
resonance. Heart. 97:632–640. 2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Reffelmann T and Kloner RA: Microvascular
reperfusion injury: Rapid expansion of anatomic no reflow during
reperfusion in the rabbit. Am J Physiol Heart Circ Physiol.
283:H1099–H1107. 2002. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yang Z, Chen P, Yu H, Luo W, Pi M, Wu Y,
Wang L, Yang F and Gou Y: Combinatorial effects of conception and
governor vessel electroacupuncture and human umbilical cord
blood-derived mesenchymal stem cells on pathomorphologic lesion and
cellular apoptosis in rats with cerebral ischemia/reperfusion. J
Tradit Chin Med. 33:779–786. 2013. View Article : Google Scholar
|
21
|
Chan W, Stub D, Clark DJ, Ajani AE,
Andrianopoulos N, Brennan AL, New G, Black A, Shaw JA, Reid CM, et
al Melbourne Interventional Group Investigators: Usefulness of
transient and persistent no reflow to predict adverse clinical
outcomes following percutaneous coronary intervention. Am J
Cardiol. 109:478–485. 2012. View Article : Google Scholar
|
22
|
Galasso G, Schiekofer S, D'Anna C, Gioia
GD, Piccolo R, Niglio T, Rosa RD, Strisciuglio T, Cirillo P,
Piscione F, et al: No-reflow phenomenon: Pathophysiology,
diagnosis, prevention, and treatment. A review of the current
literature and future perspectives. Angiology. 65:180–189. 2014.
View Article : Google Scholar
|
23
|
Rezkalla SH and Kloner RA: No-reflow
phenomenon. Circulation. 105:656–662. 2002. View Article : Google Scholar : PubMed/NCBI
|
24
|
Reffelmann T and Kloner RA: The no-reflow
phenomenon: A basic mechanism of myocardial ischemia and
reperfusion. Basic Res Cardiol. 101:359–372. 2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Niccoli G, Cosentino N, Lombardo A,
Sgueglia GA, Spaziani C, Fracassi F, Cataneo L, Minelli S, Burzotta
F, Maria Leone A, et al: Angiographic patterns of myocardial
reperfusion after primary angioplasty and ventricular remodeling.
Coron Artery Dis. 22:507–514. 2011.PubMed/NCBI
|
26
|
Poli A, Fetiveau R, Vandoni P, del Rosso
G, D'Urbano M, Seveso G, Cafiero F and De Servi S: Integrated
analysis of myocardial blush and ST-segment elevation recovery
after successful primary angioplasty: Real-time grading of
micro-vascular reperfusion and prediction of early and late
recovery of left ventricular function. Circulation. 106:313–318.
2002. View Article : Google Scholar : PubMed/NCBI
|
27
|
Rochitte CE, Lima JA, Bluemke DA, Reeder
SB, McVeigh ER, Furuta T, Becker LC and Melin JA: Magnitude and
time course of microvascular obstruction and tissue injury after
acute myocardial infarction. Circulation. 98:1006–1014. 1998.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Reffelmann T, Hale SL, Dow JS and Kloner
RA: No-reflow phenomenon persists long-term after
ischemia/reperfusion in the rat and predicts infarct expansion.
Circulation. 108:2911–2917. 2003. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kurrelmeyer KM, Michael LH, Baumgarten G,
Taffet GE, Peschon JJ, Sivasubramanian N, Entman ML and Mann DL:
Endogenous tumor necrosis factor protects the adult cardiac myocyte
against ischemic-induced apoptosis in a murine model of acute
myocardial infarction. Proc Natl Acad Sci USA. 97:5456–5461. 2000.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Croisille P, Revel D and Saeed M: Contrast
agents and cardiac MR imaging of myocardial ischemia: from bench to
bedside. Eur Radiol. 16:1951–1963. 2006. View Article : Google Scholar : PubMed/NCBI
|
31
|
Reffelmann T, Hale SL, Li G and Kloner RA:
Relationship between no reflow and infarct size as influenced by
the duration of ischemia and reperfusion. Am J Physiol Heart Circ
Physiol. 282:H766–H772. 2002. View Article : Google Scholar : PubMed/NCBI
|
32
|
Khan SQ, Ng K, Dhillon O, Kelly D, Quinn
P, Squire IB, Davies JE and Ng LL: Growth differentiation factor-15
as a prognostic marker in patients with acute myocardial
infarction. Eur Heart J. 30:1057–1065. 2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Wollert KC, Kempf T, Lagerqvist B, Lindahl
B, Olofsson S, Allhoff T, Peter T, Siegbahn A, Venge P, Drexler H,
et al: Growth differentiation factor 15 for risk stratification and
selection of an invasive treatment strategy in non ST-elevation
acute coronary syndrome. Circulation. 116:1540–1548. 2007.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Kempf T, Björklund E, Olofsson S, Lindahl
B, Allhoff T, Peter T, Tongers J, Wollert KC and Wallentin L:
Growth-differentiation factor-15 improves risk stratification in
ST-segment elevation myocardial infarction. Eur Heart J.
28:2858–2865. 2007. View Article : Google Scholar : PubMed/NCBI
|
35
|
Eggers KM, Kempf T, Lagerqvist B, Lindahl
B, Olofsson S, Jantzen F, Peter T, Allhoff T, Siegbahn A, Venge P,
et al: Growth-differentiation factor-15 for long-term risk
prediction in patients stabilized after an episode of
non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc
Genet. 3:88–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
36
|
Wollert KC: Growth-differentiation
factor-15 in cardiovascular disease: From bench to bedside, and
back. Basic Res Cardiol. 102:412–415. 2007. View Article : Google Scholar : PubMed/NCBI
|
37
|
Go LO, Murry CE, Richard VJ, Weischedel
GR, Jennings RB and Reimer KA: Myocardial neutrophil accumulation
during reperfusion after reversible or irreversible ischemic
injury. Am J Physiol. 255:H1188–H1198. 1988.PubMed/NCBI
|
38
|
Litt MR, Jeremy RW, Weisman HF,
Winkelstein JA and Becker LC: Neutrophil depletion limited to
reperfusion reduces myocardial infarct size after 90 minutes of
ischemia. Evidence for neutrophil-mediated reperfusion injury.
Circulation. 80:1816–1827. 1989. View Article : Google Scholar : PubMed/NCBI
|
39
|
Liu FC, Chuang YH, Tsai YF and Yu HP: Role
of neutrophil extracellular traps following injury. Shock.
41:491–498. 2014. View Article : Google Scholar : PubMed/NCBI
|
40
|
Huang C, Li R, Zeng Q, Ding Y, Zou Y, Mao
X, Hu W, Xiong R and Li M: Effect of minocycline postconditioning
and ischemic postconditioning on myocardial ischemia-reperfusion
injury in atherosclerosis rabbits. J Huazhong Univ Sci Technolog
Med Sci. 32:524–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
41
|
Issekutz AC, Rowter D and Springer TA:
Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in
neutrophil transendothelial migration. J Leukoc Biol. 65:117–126.
1999.PubMed/NCBI
|
42
|
Metzler B, Mair J, Lercher A, Schaber C,
Hintringer F, Pachinger O and Xu Q: Mouse model of myocardial
remodelling after ischemia: Role of intercellular adhesion
molecule-1. Cardiovasc Res. 49:399–407. 2001. View Article : Google Scholar : PubMed/NCBI
|
43
|
Eggers KM, Kempf T, Lind L, Sundström J,
Wallentin L, Wollert KC and Siegbahn A: Relations of
growth-differentiation factor-15 to biomarkers reflecting vascular
pathologies in a population-based sample of elderly subjects. Scand
J Clin Lab Invest. 72:45–51. 2012. View Article : Google Scholar
|
44
|
Wang J and Arase H: Regulation of immune
responses by neutrophils. Ann NY Acad Sci. 1319:66–81. 2014.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Yang L, Froio RM, Sciuto TE, Dvorak AM,
Alon R and Luscinskas FW: ICAM-1 regulates neutrophil adhesion and
transcellular migration of TNF-α-activated vascular endothelium
under flow. Blood. 106:584–592. 2005. View Article : Google Scholar : PubMed/NCBI
|